» Articles » PMID: 15172968

Multiple Myeloma Cells Catalyze Hepatocyte Growth Factor (HGF) Activation by Secreting the Serine Protease HGF-activator

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Jun 3
PMID 15172968
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a common hematologic neoplasm consisting of malignant plasma cells, which expand in the bone marrow. A potential key signal in the evolution of MM is hepatocyte growth factor (HGF), which acts as a potent paracrine and/or autocrine growth factor and survival factor for MM cells. Proteolytic conversion of HGF into its active form is a critical limiting step in HGF/MET signaling. Here, we show that malignant MM plasma cells convert HGF into its active form and secrete HGF-activator (HGFA), a serine protease specific for HGF activation. By using serine protease inhibitors and neutralizing antibodies, we demonstrate that HGFA produced by the MM cells is responsible for their ability to catalyze HGF activation. We, therefore, suggest that autocatalyzation of HGF conversion by MM cells is an important step in HGF/MET-induced myeloma growth and survival, which may have implications for the management of this incurable form of cancer.

Citing Articles

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures.

Dunphy K, Bazou D, Henry M, Meleady P, Miettinen J, Heckman C Cancers (Basel). 2023; 15(15).

PMID: 37568580 PMC: 10417544. DOI: 10.3390/cancers15153764.


Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.

Zhang Q, Yang Y, You X, Ju Y, Zhang Q, Sun T Front Oncol. 2023; 13:1173275.

PMID: 37546405 PMC: 10401477. DOI: 10.3389/fonc.2023.1173275.


The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma.

Giannoni P, de Totero D Cancer Drug Resist. 2022; 4(4):923-933.

PMID: 35582373 PMC: 8992445. DOI: 10.20517/cdr.2021.73.


Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin Y, de Partovi C, Berkova Z Ann Hematol. 2017; 96(6):977-985.

PMID: 28337527 PMC: 5406425. DOI: 10.1007/s00277-017-2980-3.


Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Lendvai N, Yee A, Tsakos I, Alexander A, Devlin S, Hassoun H Blood. 2016; 127(19):2355-6.

PMID: 27020089 PMC: 5003505. DOI: 10.1182/blood-2016-01-694786.